Jean B Nachega, MD, PhD, MPH

Associate Professor, Infectious Diseases and Microbiology

Associate Professor, Epidemiology


R-znvy: woa61@cvgg.rqh
Primary Phone: 967-442-2135

Personal Statement

Jean Nachega, MD, PhD, MPH, FRCP: Associate Professor of Medicine,
Infectious Diseases, Microbiology and Epidemiology, at Graduate School of
Public Health, Pittsburgh University. Dr Nachega is also an Adjunct Associate
Professor of Epidemiology and International Health at Johns Hopkins Bloomberg School of Public Health; and Professor Extraordinary of Medicine and Director of the Center for Infectious Diseases, at Stellenbosch University, Cape Town, South Africa. He received his training in Belgium (University of Louvain), UK (London School of Hygiene & Tropical Medicine), USA (Johns Hopkins University & Harvard University). He has over 25 year-experience in patient care, teaching, designing and implementing HIV/AIDS and Tuberculosis studies or programs funded by NIH/NIAID, PEPFAR, EDCTP, and Wellcome Trust. He is a lead HIV Investigator within AIDS Clinical Trial Group (ACTG) and an ad hoc consultant at WHO, CDC, Bill and Melinda Gates Foundation, as well as a member of Academy of Sciences of South Africa (ASSAf) and African Academy of Sciences (AAS)



1985 \ Facultes Universitaires Notre Dame de la Paix, Namur, Belgium\ BS (Cum Laude)
1989 \ University Catholic of Louvain, Brussels, Belgium \ MD (Cum Laude)
1999 \ Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA \ MPH
2000 \ London School of Hygiene & Tropical Medicine, London, UK \ DTM&H
2008 \ University of Cape Town, South Africa \ PhD
2010 \ Harvard School of Public Health, Boston, MA, USA \ John  McGoldrick Fellow in Biostat in AIDS Research, Decision Analysis and Health Economics


•     Primary Instructor, EPIDEM2166, Global Control of Tuberculosis and HIV, SUMMER term, Level: 2013, 6 students, 2.0 contact hours, Tues & Thurs, 4 weeks (One Credit)

Selected Publications

1) Uthman OA, Okwundu C, Gbenga K, Volmink J, Dowdy D, Zumla A, Nachega JB. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults with Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):32-9. PMID: 26148280 (Impact Factor: 17.202). 


2) Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis. 2014 May;58(9):1297-307. PMID:24457345 (Impact Factor: 8.886; cited by over 90 PubMed Central articles) 


3) Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, Orrell C, Altice FL, Bangsberg DR, Bartlett JG, Beckwith CG, Dowshen N, Gordon CM, Horn T, Kumar P, Scott JD, Stirratt MJ, Remien RH, Simoni JM, Nachega JB. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012 Jun 5;156(11):817-33. PMID: 22393036. (Impact Factor: 17, cited by over 100 PubMed Central articles). 


4) Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, Mills EJ, Ho YS, Stringer JS, McIntyre JA, Mofenson LM. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS. 2012 Oct 23;26(16):2039-52. PMID:22951634 (Impact Factor: 4.555; cited by over 100 PubMed Central articles) 


5) Nachega JB, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, Morroni C, Schoeman H, Knowlton AR, Maartens G.Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010 Jun 1;24(9):1273-80. PMID: 20453627 (Impact Factor: 5.54; cited by 39 PubMed Central articles) 


6) Nachega JB, Leisegang R, Bishai D, Nguyen H, Hislop M, Cleary S, Regensberg L, Maartens G. Association of antiretroviral therapy adherence and health care costs. Ann Intern Med. 2010 Jan 5;152(1):18-25. PMID:20048268 (Impact Factor: 17.202).


7) Nachega JB, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, Cotton M, Maartens G. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr. 2009 May 1;51(1):65-71. PMID: 19282780 (Impact Factor: 4.556, cited by over 100 PubMed Central articles).  


8) Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, Frank I, Maartens G, Nachega JB. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008 May 20;5(5):e109. PMID: 18494555 (Impact Factor: 13.585; cited by 69 PubMed Central articles) 


9) Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007 Apr 17;146(8):564-73. PMID:17438315. (Impact Factor: 17.202; cited by over 100 PubMed Central articles)


10)  Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006 Aug 9;296(6):679-90. PMID: 16896111 (Impact Factor: 44.405; cited by over 100 PubMed Central articles)


11) Bulabula ANH, Nelson JA, Musafiri EM, Machekano R, Sam-Agudu NA, Diacon, AH, Shah M, Creswell J, Theron G, Warren RM, Jacobson KR, Chirambiza JP, Kalumuna D, Bisimwa BC, Katoto PDMC, Kaswa MK, Birembano FM, Kitete L,Grobusch MP, Kashongwe ZM, Nachega JB. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. Clin Infect Dis. 2019 Feb 13. Ahead of Print.

Jean B Nachega